Xihuang pill suppressed primary liver cancer growth by downregulation of AFP and YAP signaling
XHP inhibited PLC growth by suppressing AFP and YAP signaling. This study provides an experimental basis for XHP application in PLC treatment.
Authors
- Yu Tang (ORCID: https://orcid.org/0000-0002-7067-8066)
- Jingxiao Wang (ORCID: https://orcid.org/0000-0002-7799-781X)
- Zhihan Li (ORCID: https://orcid.org/0009-0001-7087-2387)
- Zhang Wang (ORCID: https://orcid.org/0000-0001-6169-1755)
- Jiabo Wang (ORCID: https://orcid.org/0000-0001-8070-9543)
- Shuyang Wang
- Yuewen Dai
- Lihui Yang
- Zhen Huang (ORCID: https://orcid.org/0000-0001-5591-7340)
- Qing Pu
- Wantao Yu (ORCID: https://orcid.org/0009-0006-1222-9656)
- Sha Luo (ORCID: https://orcid.org/0000-0002-0507-0273)
- Tianyi Yang
Institutions
- Beijing University of Chinese Medicine (CN)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- State Administration of Traditional Chinese Medicine of the People's Republic of China (CN)
- Second Affiliated Hospital of Xi'an Jiaotong University (CN)
- Beijing Hospital of Traditional Chinese Medicine (CN)
- Beijing Fengtai Hospital (CN)
- Chengdu University of Traditional Chinese Medicine (CN)
- Tsinghua University (CN)
Publication Details
- Journal
- Journal of Ethnopharmacology
- Published
- 2025-04-26
- DOI
- https://doi.org/10.1016/j.jep.2025.119891
- Citations
- 3
- Primary Topic
- Hippo pathway signaling and YAP/TAZ
- Type
- article
- Field-Weighted Citation Impact
- 3.45
Funders
- National Natural Science Foundation of China
- China Academy of Chinese Medical Sciences
- Beijing Nova Program